Published in final edited form as:

J Am Chem Soc. 2011 January 19; 133(2): 239–251. doi:10.1021/ja104433n.

Controlling and Fine Tuning the Physical Properties of Two Identical Metal Coordination Sites in *De Novo* Designed Three Stranded Coiled Coil Peptides

Olga Iranzo^{†,‡,#}, Saumen Chakraborty^{†,#}, Lars Hemmingsen[‡], and Vincent L. Pecoraro[†]

[†]Department of Chemistry, University of Michigan, Ann Arbor, MI 48109, USA, Fax: (+1) 734-936-7628, vlpec@umich.edu

[‡]Instituto de Tecnologia Química e Biológica, Universidade Nova de Lisboa, Avenida República, EAN, 2785-572 Oeiras, Portugal

[#]Department of Basic Sciences and Environment, University of Copenhagen, Thorvaldsensvej 40, 1871 Frederiksberg, Denmark

Abstract

Herein we report how *de novo* designed peptides can be used to investigate whether the position of a metal site along a linear sequence that folds into a three stranded α -helical coiled coil defines the physical properties of Cd(II) ions in either CdS₃ or CdS₃O (O-being an exogenous water molecule) coordination environments. Peptides are presented that bind Cd(II) into two identical coordination sites that are located at different topological positions at the interior of these constructs. The peptide GRANDL16PenL19IL23PenL26I binds two Cd(II) as trigonal planar 3-coordinate CdS₃ structures whereas GRANDL12AL16CL26AL30C sequesters two Cd(II) as pseudotetrahedral 4-coordinate CdS₃O structures. We demonstrate how for the first peptide, having a more rigid structure, the location of the identical binding sites along the linear sequence does not affect the physical properties of the two bound Cd(II). However, because these are rigid aggregates, the sites are not completely independent as Cd(II) bound to one of the sites (¹¹³Cd NMR chemical shift of 681 ppm) is perturbed by the metallation state (apo or [Cd(pep)(Hpep)₂]⁺ or [Cd(pep)₃][−]) of the second center (¹¹³Cd NMR chemical shift of 686 ppm).

GRANDL12AL16CL26AL30C shows a completely different behavior. The physical properties of the two bound Cd(II) ions indeed depend on the position of the metal center, having pK_{a2} values for the equilibrium [Cd(pep)(Hpep)₂]⁺ → [Cd(pep)₃][−] + 2H⁺ (corresponding to deprotonation and coordination of cysteine thiols) that range from 9.9 to 13.9. In addition, the L26AL30C site shows dynamic behavior, which is not observed for the L12AL16C site. These results indicate that for

Correspondence to: Vincent L. Pecoraro.

[#]These authors contributed equally.

Supporting Information Available: Model and derivation of the pK_{a2} fitting equations for the dual site peptides, Table of the thermodynamic parameters determined from GuHCl-induced unfolding curves of peptides GRANDL26AL30C, GRANDL12AL16C, and GRANDL12AL16CL26AL30C, GuHCl denaturation titration curves of GRANDL12AL16C, GRANDL26AL30C, GRANDL12AL16CL26AL30C and GRANDL12AL16CL26AL30CL33I at pH 6.5, ¹¹³Cd NMR of [Cd(II)(H₂O)]¹⁶[apo]³⁰ (GRANDL12AL16CL26AL30C)₃[−] at pH 6.0, ¹¹³Cd NMR of (GRANDL12AL16CL26AL30C) with 1.0 eq ¹¹³Cd(II) at pH 8.5, NOESY spectrum of GRANDL12AL16CL26AL30C showing sequential assignments of backbone amide protons, sections of NOESY spectra for GRANDL12AL16CL26AL30C in the presence of 2.0 equivalents of Cd(II) at different pH values, overlay of simulated and experimental UV-Vis pH titration curves of GRANDL12AL16CL26AL30C and part of the assignment. This material is available free of charge via the Internet at <http://pubs.acs.org>.

It should be noted that there is not a 100% correspondence between the ¹¹³Cd NMR shifts and the ^{111m}Cd PAC assessments of the CdS₃/CdS₃O ratio. Quantum chemical calculations show that a change in Cd-S bond length of 0.01 Å can cause a change in ¹¹³Cd NMR chemical shift of ~20 ppm (Hemmingsen *et al.* unpublished results). Thus, the PAC data often indicate a higher percentage of CdS₃ in these samples than one would predict using the strict NMR correlation.

these systems one cannot simply assign a “4-coordinate structure” and assume certain physical properties for that site since important factors such as packing of the adjacent Leu, size of the intended cavity (*endo* vs *exo*) and location of the metal site play crucial roles in determining the final properties of the bound Cd(II).

Introduction

Over the last two decades the emerging field of *de novo* metalloprotein design has empowered chemists to understand biologically relevant metal binding sites at a molecular level and gain important fundamental knowledge on how the protein matrix influences and controls the metal ion properties.^{1–3} Owing to significant advances in peptide synthesis, computational and structural biology it has become possible to design linear amino acid sequences that generate scaffolds with a well defined secondary and tertiary structure. This approach allows one to elucidate, in a systematic manner, structural features and elements that play crucial roles in determining the coordination geometries and physical properties of metal ions, as well as their site specificity. This degree of knowledge is necessary not only to comprehend fully how metalloproteins work and fine tune the metal ion geometries and properties, but also for the design of new bio-molecules with improved properties and new functionalities. Given this promise, it is not surprising that this research field is attracting a significant amount of attention as is shown by the reviews that have appeared recently.⁴

One of the most targeted secondary structural motifs in the *de novo* peptide design field is the α -helix and in general it has been used to generate α -helical coiled coils and bundle structures. These helical aggregates result from sequences containing a seven-residue [heptad] repeat, denoted [**abcdefg**]_n, that typically has hydrophobic residues at **a** and **d** positions, and polar or charged residues at **e** and **g** positions. Despite this apparently simple pattern, the heptad repeat approach has shown its high versatility and potential. A wide variety of *de novo* designed structures has already been reported which differ in the nature (homomers/heteromers), number (from dimers to heptamers) and alignment (parallel/antiparallel) of the helices.⁵ From an inorganic chemical point of view, these structures represent perfect scaffolds where diverse metal ion binding sites can be engineered. Indeed, this strategy has been employed by several research groups to design metallopeptides with specified characteristics.

Two major strategies have been employed to introduce metal ion binding sites into these helical scaffolds: a) the use of cofactors, mainly heme units, or b) the replacement of the amino acids in the hydrophobic cores by amino acids with metal ion coordinating properties. The Dutton and Gibney groups have used four-helix bundles as maquettes to study heme containing proteins.^{6–9} Gibney and coworkers also used the maquette motifs to develop a prototype ferredoxin maquette, a peptide-based synthetic analogue of natural [4Fe-4S]^{2+/+} proteins.¹⁰ DeGrado,^{11–12} Ghirlanda,¹³ Lombardi and Pavone,¹⁴ Mihara,^{15–16} and their co-workers also used this approach to prepare different coiled coils and helical bundles which can bind between one and four heme units depending on the design. The second strategy was used by DeGrado and co-workers to design the dueferri (DF) peptides, a family of four-helix bundles, that contain a Glu₄-His₂ metal binding site capable of coordinating 2 equivalents of Fe(II), Mn(II) and Zn(II). These *de novo* designed metallopeptides are paradigms for di-iron, di-manganese and di-zinc proteins.^{17–18} The Ogawa group has designed Cys containing peptides which assemble into coiled coils upon binding Cd(II) and Cu(I), forming a CdS₄ and a Cu₄S₄ center, respectively.^{19–20} On the same line, using Cys or His as donor ligands, Tanaka and co-workers designed peptides that bound Hg(II) and Cd(II),²¹ and Ni(II), Zn(II), Co(II) and Cu(II),^{22–24} respectively. These last systems^{19–23} and others^{25–26} displayed metal-ion induced self-assembly.

Before one can use *de novo* design for the more lofty goal of chemical catalysis it is important to understand how to control the coordination environment of what would be the resting state of the active site. To this end, our group has used the *de novo* design approach to define the chemistry of Cd(II), Hg(II), As(III) and Pb(II) in thiolate rich environments, with particular emphasis on controlling the coordination number of the bound ions. Using the heptad repeat approach, we have described how (above pH 5.5) the parent peptide **TRI** (Table 1)²⁷ associates in aqueous solution to form parallel, three-stranded coiled coils. These aggregates bind metals in a sulfur rich environment ranging from HgS₂ (linear), HgS₃ (trigonal planar) and HgS₄ (tetrahedral) to As(III)S₃ (trigonal pyramidal).^{28–31} We have also prepared peptides that contain either Cys or the non-coded amino acid analogue Pen (penicillamine) in their interiors, binding Cd(II) with high affinity and different coordination geometries. Substitution of the Leu by Cys or Pen generates partially or fully preorganized homoleptic thiol-rich binding sites inside the hydrophobic core of these coiled coils. By combining ¹¹³Cd NMR and ^{111m}Cd Perturbed Angular Correlation (PAC) spectroscopy, we have shown how the peptide **TRI**L16C binds Cd(II) as a mixture of pseudotetrahedral (CdS₃O) and trigonal planar (CdS₃) structures.³² Complete control of the Cd(II) coordination number was achieved by modifying the sterics in the metal ion binding site through changes in the amino acids of either the first or second coordination sphere. Namely, removal of steric bulk directly above the Cys plane by replacement of a Leu with an Ala generated the peptide **TRI**L12AL16C that binds Cd(II) exclusively in the CdS₃O geometry.^{33,34} On the other hand, the pure CdS₃ geometry was achieved by increasing steric constraints around the metal ion binding site. Two different approaches were used in the latter case, both employing non-natural amino acids, a key benefit of the chemical peptide synthesis. In the first approach, Cys was replaced by Pen which has bulky methyl groups replacing the β-methylene hydrogen atoms (peptide **TRI**L16Pen).³⁴ In the second strategy, the chirality of the Leu just above the Cys was modified (L-Leu was replaced by D-Leu) and as a consequence, the side chain of the Leu was reoriented towards the C termini and towards the metal ion binding site (peptide **TRI**L12L_DL16C).³⁵ This knowledge has driven our design strategy for the heterochromic peptides, **GRAND**L16PenL26AL30C and **GRAND**L12L_DL16CL26AL30C.^{35,36} These peptides, containing two binding sites in close proximity (~ 20 Å) within the same three-stranded coiled coil, are capable of binding two Cd(II) ions with different coordination geometries (three coordinate, trigonal planar as CdS₃ and four coordinate, pseudotetrahedral as CdS₃O) and thus different physical properties. Furthermore, these peptides show site-selective Cd(II) recognition, where in both peptides, Cd(II) binds selectively to the 4-coordinate site (CdS₃O) regardless of the pH conditions. These heterochromic peptides are important achievements towards our goal of preparing designed metalloproteins which contain both structural and catalytic sites.

While heterochromic peptides allowed us to discriminate between 3 and 4- coordination sites that were at first glance nearly identical, this success raised an important new question: Are all 3-coordinate or 4-coordinate sites in the same peptide identical? Said differently, can we refer to, as an example, an environment simply as a 4-coordinate site or must we specify whether this sulfur rich environment is in the center of the helix versus an end or whether the Cys resides in **a** vs **d** heptad positions? And, if there is a difference, will the physical properties of the center be modified, the selectivity for binding sites or the dynamics of the structures be different? Ultimately, we can address whether the position of these sites in the coiled coil play any role in fine tuning the physical properties of the bound Cd(II).

To address these issues we have designed sets of single peptides capable of binding two equivalents of Cd(II) with the same coordination geometry. A construct such as this will have two 3-coordinate sites (CdS₃) or two 4-coordinate sites (CdS₃O) at different positions in the coiled coil. Figure S1 shows models for these two constructs created in Pymol.³⁷ These peptides would allow us to assess directly the selectivity of metal binding between

two equivalent positions within the peptide, whether binding of one metal would influence the physical properties of the second bound metal and if different physical properties can be observed for the same metal in two similar first coordination environments but in different topological positions within the coiled coil. With the constructs described herein, we address the important issues of how the specific position of these sites could modify the intrinsic properties of the bound Cd(II). We conclude that the 4-coordinate site is more sensitive to these changes than the 3-coordinate site, and discuss how the final physical properties of the 4-coordinate site can be modified by the intrinsic nature of the local peptide environment.

Experimental Section

The nomenclature used to describe the metal complexes prepared in this study is provided in ref [38].

Peptide Synthesis and Purification

The **TRI** and **GRAND** peptides (see Table 1 for sequence nomenclature) were synthesized on an Applied Biosystems 433A peptide synthesizer using standard Fmoc protocols,³⁹ and purified and characterized as described previously.²⁹

Ultraviolet-Visible (UV-Vis) Spectroscopy

All solutions were purged with argon before use to minimize the chances of oxidation of the peptides and formation of disulfide bonds. Fresh stock solutions of the purified peptides were prepared for each experiment in doubly distilled water and their concentrations determined by quantization of the Cys thiol groups using a known assay with 4,4'-dipyridyl disulphide.⁴⁰

a) Metal Binding Titrations—Cd(II) into peptide titrations were performed at room temperature on a Cary 100 Bio UV-Vis spectrometer using a 1-cm quartz cuvette. Aliquots of 8.93 mM CdCl₂ stock solution were added into a 3-mL solution containing 60 μM peptide and 50 mM appropriate buffer (TRIS for pH 8.5 and CHES for pH 9.0 and 9.5). In each case, the difference spectra were obtained by subtracting the background spectrum of the peptide in the absence of metal (60 μM peptide and 50 mM appropriate buffer).

b) pH Titrations—UV-Vis pH titrations were carried out at room temperature on an Ocean Optics SD 2000 fiber optic spectrometer and the pH measured using a mini-glass combination pH electrode (Hamilton Biotrode) coupled to a Fisher Accumet digital pH meter model 805 MP. pH Titrations were performed by adding small aliquots of concentrated solution of KOH to unbuffered solutions containing CdCl₂ (20 – 40 μM) and peptide (60 – 120 μM), and monitoring the change in absorbance at 235 nm as a function of pH. Equilibration time was always allowed before reading the final pH. In all cases, reverse titrations were carried out by adding small aliquots of concentrated solution of HCl to verify the reversibility of the process. The UV-Vis pH titration curves of the peptides containing a single binding site were fit using the model and procedure published previously for the release of two protons upon Cd(II) binding to the three Cys thiolates.^{41,42} The experimental data for the peptides **GRANDL12AL16CL26AL30C** and **GRANDL16PenL19IL23PenL26I** were fit using a model that was derived from the single binding site model, taking into account the two binding sites and the non-specific binding of Cd(II), as it was observed in the ¹¹³Cd NMR experiments (see Supporting Information for a full description of the model and the Results section for the ¹¹³Cd NMR experiments). The same model was applied to fit the experimental data for the peptide **GRANDL12AL16CL26AL30CL33I**.

CD Spectroscopy

All Circular Dichroism data were collected using an Aviv model 202 thermostatically controlled Circular Dichroism Spectrometer equipped with a 450 watt Xenon arc lamp. GuHCl titration experiments were carried out using a Microlab 500 series syringe pump automatic titrator controlled by Aviv software. Titrations were carried out by mixing two separate solutions of peptide containing 0.0 and 7.63 M GuHCl. Refractive index measurements were used to determine the concentration of the stock GuHCl solution.⁴³ Each of these solutions contained 10 μ M monomer peptide and 10 mM phosphate buffer. The pH values were adjusted to 6.5 by adding KOH or HCl. Titrations were performed at 25°C in a rectangular open top quartz cell of 1 cm path length. The observed ellipticity in millidegrees were plotted vs. increasing GuHCl concentration. Whenever necessary, the data were fit by nonlinear least-square methods to a two-state trimer-monomer equilibrium⁴⁴ using the software Igor Pro (Wavemetrics, Inc). Midpoint values of the experimental curves were calculated from the concentration of GuHCl where the ellipticity is 50% from the starting ellipticity in the absence of denaturant.

¹¹³Cd NMR Spectroscopy

All the spectra were collected at room temperature on a Varian Inova 500 spectrometer (110.92 MHz for ¹¹³Cd) equipped with a 5 mm broadband probe. ¹¹³Cd NMR spectra were externally referenced to a 0.1 M Cd(ClO₄)₂ solution in D₂O. A spectral width of 847 ppm (93,897 Hz) was sampled using a 5.0 μ s 90° pulse and 0.05 second acquisition time with no delay between scans. Samples were prepared under a flow of argon by dissolving 30 – 35 mg of the lyophilized and degassed peptides in 450 – 500 μ L 15% D₂O/H₂O solution. The peptide concentrations were determined by using the assay with 4,4'-dipyridyl disulphide,⁴⁰ and the concentrations range from 9 to 18 mM peptide, which corresponds to 3 – 6 mM three-stranded coiled coil. The final samples were prepared by the addition of the appropriate amount of 250 mM ¹¹³Cd(NO₃)₂ solution (prepared from 95 % isotopically enriched ¹¹³CdO obtained from Oak Ridge National Laboratory) and the adjustment of the pH with KOH or HCl solutions. The pH value was measured both before and after the experiment. An argon atmosphere was maintained when possible but the samples came in contact with O₂ during addition of ¹¹³Cd(NO₃)₂, pH adjustment and acquisition. The data were analyzed using the software MestRe-C.⁴⁵ All free induction decays (FID's) were zero filled to double the original points and were processed by application of 100 Hz line broadening prior to Fourier transformation.

¹H NMR Spectroscopy

2D ¹H NMR experiments were performed at room temperature on a 500 MHz Varian Inova spectrometer equipped with an inverse detection probe. Samples were prepared by dissolving 30–35 mg of lyophilized and degassed peptide in 500–600 μ L 10% D₂O/H₂O under a flow of argon. Final solutions contained 3.0 – 4.0 mM of peptide trimer, as determined by the assay with 4,4'-dipyridyl disulphide.⁴⁰ Whenever necessary ¹¹³Cd(II) was added in the form of 250 mM ¹¹³Cd(NO₃)₂ stock solution and pH was adjusted with concentrated KOH or HCl solutions as described in the previous section. Attempts were made to keep an argon atmosphere throughout, but the samples did come into contact of air during addition of ¹¹³Cd(NO₃)₂, pH adjustment and data acquisition. Nuclear Overhauser Effect Spectroscopy (NOESY) experiments were performed using standard Varian pulse sequences with mixing time of 100 ms.⁴⁶ For water suppression, pre-saturation was used for 1.5 s with saturation power of 5 dB.⁴⁷ A spectral window of 11.2 ppm was sampled with 2048 points and 256 increments in the indirect dimension with 8 scans. Z-gradient Total Correlation Spectroscopy (ZTOCSY) experiment was performed only for the apo peptide under similar conditions with spin lock field strength of 7 kHz for the 90° pulse.⁴⁸ An 80

ms spin lock was used during the experiment. All the data were processed by MestRe Nova.
49

¹¹¹mCd Perturbed Angular Correlation (PAC) Spectroscopy

All ¹¹¹mCd PAC experiments and sample preparation were performed as described previously.^{42,50,51} The final volume of the samples ranged between 0.05 and 0.5 mL with concentrations of 250 – 300 μM peptide, 20 mM appropriate buffer (MES for pH values 6.5 and 7.0, and CHES for pH values between 8 and 9.3) and different Cd(II)/peptide ratios (Table 3). All fits were carried out with 300 data points, disregarding the first 5 points due to systematic errors in these. All PAC spectra were initially analyzed with four NQIs (vide infra), and NQIs were included in the fit if the amplitude was larger than two times the standard deviation. Each nuclear quadrupole interaction (NQI) was modeled using a separate set of parameters that includes ω_0 , η , $\Delta\omega_0/\omega_0$, $1/\tau_c$ and A. The parameter ω_0 ($\omega_0 = 12\pi|eQV_{zz}|/(40h)$, where Q is the nuclear electric quadrupole moment and V_{zz} is the numerically largest component of the diagonalized electric field gradient tensor) is associated with the strength of the interaction between the surrounding charge distribution and the Cd nucleus, η is the so-called asymmetry parameter which is 0 in an axially symmetric complex and has a maximal value of 1; $\Delta\omega_0/\omega_0$ describes static structural variations from one Cd(II) site to the next, and is as such a measure of the structural variability; τ_c is the rotational correlation time; and A is the amplitude of the signal (see ref [32] for a more detailed description). The rotational correlation time was constrained to be the same for all NQIs in a given spectrum. The parameters fitted to the PAC data are presented in Table 3. In two cases $\Delta\omega_0/\omega_0$ was fixed to 15 %, denoted with “d” in Table 3. Setting the parameter free in the fit lead to very large values, and fixing it did not alter the reduced chi-square.

Results

Cd(II) Binding to the GRAND peptides

The stoichiometry and the pH dependence of the binding of Cd(II) to the **GRAND** peptides were monitored by UV-Vis spectroscopy using the ligand-to-metal charge-transfer (LMCT) band at 235 nm corresponding to the formation of Cd-S bonds in CdS₃ or CdS₃O complexes.

a) Stoichiometry—The addition of Cd(II) aliquots into the different solutions containing 60 μM (20 μM trimer) **GRAND** peptides at pH values where, based on the pH titrations, the peptides are capable of fully binding the Cd(II), generated the appearance of the characteristic LMCT. Shown in Figure 1 are the titration curves obtained by plotting the increase in absorbance vs the equivalents of Cd(II) added per trimer of **GRAND** peptides. In all cases the curves plateau at 2(±0.14) equivalents of Cd(II). The different observed final absorbance values reflect the higher extinction coefficient of the 3-coordinated CdS₃ species compared to the 4-coordinate CdS₃O species at 235 nm.^{34,36}

b) pH dependence—The increase in pH of a solution containing 40 μM Cd(II) and 60 μM (20 μM trimer) **GRAND**L16PenL19IL23PenL26I enhances the 235 nm LMCT transition with Figure 2 showing this pH titration curve (green). The equivalent titration curve with **GRAND**L12AL16CL26AL30C is shown in blue indicating binding of Cd(II) at lower pH values. The shape of these pH titration curves is consistent with the release of four protons upon binding of two equivalents of Cd(II) and, therefore, it is in agreement with our published model for the simultaneous release of the final two protons upon Cd(II) binding to the remaining two thiolates of either Cys or Pen ([Cd(pep)(Hpep)₂]⁺ species to give the [Cd(pep)₃][−]).^{41,42} However, unlike the pH titration curve obtained for the peptide **GRAND**L16PenL26AL30C (Figure 2, red), where two well-defined regions were observed

allowing for the independent analysis of both sites,³⁶ only one inflexion point was obtained for the peptides $\text{GRANDL16PenL19IL23PenL26I}$ and $\text{GRANDL12AL16CL26AL30}$. These results point out that in these **GRAND** peptides both sites bind Cd(II) at similar pH values. In these cases, and taking into account the ^{113}Cd NMR pH titrations (see below), the experimental data were fit to a model where binding of two equivalents of Cd(II) occurs simultaneously to both sites (see Experimental section and Supporting Information for the full description). The resulting $\text{p}K_a$ values are reported in Table 2.

CD Spectroscopy

The stabilities of the peptides GRANDL26AL30C , GRANDL12AL16C , $\text{GRANDL12AL16CL26AL30C}$ and $\text{GRANDL12AL16CL26AL30CL33I}$ were assessed from their GuHCl-induced unfolding titration curves at pH 6.5. The observed ellipticity in millidegree as a function of denaturant concentration was plotted to generate the titration curves (Figure S2). GRANDL26AL30C with a denaturation midpoint of 3.7 M (magenta) shows that this is the most stable construct followed by GRANDL12AL16C (midpoint 3.3 M, red), $\text{GRANDL12AL16CL26AL30CL33I}$ (midpoint 2.9 M, green) and $\text{GRANDL12AL16CL26AL30C}$ (midpoint 1.7 M, blue). The shape of the denaturation titration curve for $\text{GRANDL12AL16CL26AL30CL33I}$ is different from the other peptides, which suggests that the Ile group has most likely modified the trimer-monomer two state equilibrium. Fits to the experimental curves were performed as described in the Experimental Section for the peptides GRANDL26AL30C , GRANDL12AL16C and $\text{GRANDL12AL16CL26AL30C}$ only (Table S1, Figure S2).

^{113}Cd NMR Spectroscopy

The ^{113}Cd NMR spectra of $\text{GRANDL16PenL19IL23PenL26I}$ (Figure 3, green) and $\text{GRANDL12AL16CL26AL30}$ (Figure 3, blue) were recorded in the presence of two equivalents of $^{113}\text{Cd}(\text{NO}_3)_2$ at pH 9.5 and 8.5, respectively. Two resonances were observed in each case with chemical shifts of 686 and 681 ppm for $\text{GRANDL16PenL19IL23PenL26I}$, and 589 and 572 ppm for $\text{GRANDL12AL16CL26AL30}$. ^{113}Cd NMR pH titrations were carried out for both peptides. The pH of a solution containing 3.0 mM $(\text{GRANDL16PenL19IL23PenL26I})_3$ and two equivalents of $^{113}\text{Cd}(\text{NO}_3)_2$ was varied from pH 7.5 to 9.5 and the ^{113}Cd NMR recorded (Figure 4A). Three resonances were observed at pH 7.5 with chemical shifts of 681, 686 and 691 ppm. An increase in pH led to decreased intensity of the resonance at 691 ppm and an increase of the resonance at 681 ppm. The resonance at 686 ppm increased continuously. By pH 9.5, only the resonances at 681 and 686 ppm were observed. The analogous experiment with 3.0 mM $(\text{GRANDL12AL16CL26AL30})_3$ and two equivalents of $^{113}\text{Cd}(\text{NO}_3)_2$ was carried out between pH 6.0 and 8.5 (Figure 5). All the spectra showed two resonances with chemical shifts of 589 and 572 ppm. The ^{113}Cd NMR spectrum of 3.3 mM $(\text{GRANDL12AL16CL26AL30C})_3$ in the presence of 1.0 eq of $^{113}\text{Cd}(\text{NO}_3)_2$ at pH 6.0 showed a single resonance at 572 ppm (Figure S3). To determine if these peptides show site-selective binding of Cd(II), experiments were carried out where an aliquot of 1.0 equivalents of $^{113}\text{Cd}(\text{NO}_3)_2$ was added to a solution containing 3.3 mM $(\text{GRANDL16PenL19IL23PenL26I})_3$ at pH 9.5 or 3.0 mM $(\text{GRANDL12AL16CL26AL30})_3$ at pH 8.5. Three resonances with chemical shifts of 681, 686 and 691 ppm were observed for $\text{GRANDL16PenL19IL23PenL26I}$ (Figure 4B), similar to those observed at low pH under stoichiometric conditions. For $\text{GRANDL12AL16CL26AL30}$, the ^{113}Cd NMR spectrum (Figure S4) showed two peaks at 589 and 572 ppm.

^{111}mCd PAC Spectroscopy

^{111}mCd PAC spectroscopy was used to determine the Cd(II) coordination geometry of the different complexes $[\text{Cd}(\text{II})(\text{H}_2\text{O})](\text{GRANDL26AL30C})_3^-$, $[\text{Cd}(\text{II})]^{16}[\text{Cd}(\text{II})(\text{H}_2\text{O})]^{30}(\text{GRANDL16PenL26AL30C})_3^{2-}$, $[\text{Cd}(\text{II})(\text{H}_2\text{O})]_2(\text{GRANDL12AL16CL26AL30C})_3^{2-}$ and

$[\text{Cd}(\text{II})]_2(\text{GRANDL16PenL19IL23PenL26I})_3^{2-}$. The ^{111}mCd PAC spectra obtained are shown in Figure 6. The PAC data were analyzed as described in the Experimental Section and the fitted parameters are reported in Table 3. The observed values of ω_0 , giving information regarding the first coordination sphere ligands, fall into four frequency regions: 1) NQI1: high frequency signal ($\omega_0 \sim 0.457\text{--}0.461$ rad/ns) assigned to a trigonal CdS_3 structure;^{32,34} 2) NQI2: ($\omega_0 \sim 0.342\text{--}0.349$ rad/ns) assigned to a tetrahedral CdS_3X structure (where X may be H_2O);^{32,34} 3) NQI3: ($\omega_0 \sim 0.242\text{--}0.255$ rad/ns) probably reflecting a coordination geometry with 2–3 Cys and 1–2 other N or O containing ligands; and, 4) NQI4: a low frequency signal ($\omega_0 \sim 0.105\text{--}0.159$ rad/ns giving rise to a broad feature around $0.140\text{--}0.200$ rad/ns in the spectra) which is present in almost all spectra and likely represents one or several $\text{Cd}(\text{II})$ non-specifically bound species coordinated to the carboxylate groups at the interface of the helices forming the coiled coils. This NQI4 represents only a minor fraction of the signal and, therefore, it is difficult to obtain a good fit of the PAC parameters. Since it is a small and common feature in the spectra, we will not comment on it further.

The PAC spectrum of GRANDL26AL30C with 1/12 $\text{Cd}(\text{II})$ /peptide ratio at pH 7.0 shows the signatures corresponding to NQI2 ($\omega_0 = 0.348$ rad/ns) and NQI3 ($\omega_0 = 0.245$ rad/ns). Also, a minor fraction of NQI4 was observed. A very similar spectrum was obtained for the same peptide with 1/12 $\text{Cd}(\text{II})$ /peptide ratio at pH 9.1 (Figure 6) and the fitting of the experimental data gave the same prominent NQIs (NQI2 and NQI3, Table 3). NQI4 was not significantly present in this dataset. The PAC spectra of $\text{GRANDL16PenL26AL30C}$ with 1/12 $\text{Cd}(\text{II})$ /peptide ratio at pH 6.5 and 9.3 are highly similar to those observed for GRANDL26AL30C and can be analysed with essentially the same NQIs (NQI2, NQI3, and NQI4) with minor variations in the relative amplitudes. When at pH 9.3 the ratio of $\text{Cd}(\text{II})$ to peptide was increased to achieve the loading of both binding sites (1.85/3 $\text{Cd}(\text{II})$ /peptide ratio), the high frequency signal (NQI1) appeared in addition to the features corresponding to the three NQIs found at low $\text{Cd}(\text{II})$ /peptide ratio (Figure 6). Thus, the data indicate that the CdS_3 site is only occupied at high $\text{Cd}(\text{II})$ /peptide ratios. The PAC spectra obtained for the $\text{GRANDL12AL16CL26AL30C}$ peptide at pH 8.7 under conditions that favour loading of both binding sites (1.85/3 $\text{Cd}(\text{II})$ /peptide ratio) gives a PAC signal with the signature of the L26AL30C site but with a more prominent NQI2 ($\omega_0 = 0.342$ rad/ns). The origin of this increase in amplitude for NQI2 is attributed to the binding of $\text{Cd}(\text{II})$ to the L12AL16C site, which is supported by the fact that $\text{Cd}(\text{II})$ binds to this site as a single CdS_3O species (as observed for TRL12AL16C).³⁴ Interestingly, all peptides investigated with PAC spectroscopy in this work and containing the L26AL30C site display this signature: a mixture of NQI2, NQI3, and possibly NQI4 (minor fraction), suggesting structural variability. The PAC spectrum of the peptide $\text{GRANDL16PenL19IL23PenL26I}$ recorded at pH 9.2 and high $\text{Cd}(\text{II})$ concentration (1.85/3 $\text{Cd}(\text{II})$ /peptide ratio, Figure 6) shows a single prominent signal in the high frequency range. Since this high frequency signal can be fitted with just one NQI, corresponding to NQI1 (trigonal CdS_3), the two binding sites in the triple helix formed by this peptide appear to have highly similar structures.

¹H NMR Spectroscopy

To ascertain the site specificity of $\text{Cd}(\text{II})$ binding to $\text{GRANDL12AL16CL26AL30C}$ at pH 6.0 further, we used two-dimensional NMR spectroscopy. The backbone resonances of the peptide were assigned using NOESY and TOCSY spectra, (Figure S5 shows the sequential assignment of amide protons (H^{N}) of Glu7 to Leu33). Using this information, β methylene protons (H^{β}) of each Cys residues were identified. NOESY spectra were used to monitor the progress of $\text{Cd}(\text{II})$ titration into 3.25 mM ($\text{GRANDL12AL16CL26AL30C}$)₃ at pH 6.0 by observing changes in the $\text{H}^{\text{N}}\text{--}\text{H}^{\beta}$ cross peak region of Cys (Figure 7). The horizontal axis on Figure 7 corresponds to the H^{N} and the vertical axis corresponds to the H^{β} of each Cys. Two non-equivalent H^{β} appear as separate cross peaks corresponding to each H^{N} . The regions a

(7.72 ppm) and **c** (8.07 ppm) of Figure 7 correspond to cross peaks of $H^N_{16}-H^{\beta}_{16}$ and $H^N_{30}-H^{\beta}_{30}$, respectively. Two sets of additional cross peaks at 7.57 ppm and 8.17 ppm correspond to interresidue cross peaks between H^N of Lys17 and H^{β} of Cys16 and between H^N of Lys31 and H^{β} of Cys30, respectively. These peaks contain redundant information as regions **a** and **c** in the figure and will not be considered further. The cross peak at 7.91 ppm can be best assigned as H^N-H^{γ} cross peak of Glu21. After the addition of 0.5 and 1.0 eq of $^{113}\text{Cd}(\text{NO}_3)_2$ the major cross peak at 7.81 ppm appears, marked as region **b**. This new peak is broad along the F1 dimension and is an overlap of the two individual H^{β} resonances of Cys16 which are perturbed due to Cd(II) binding to Cys16. These results display preferential binding of Cd(II) to the Cys16 site at pH 6.0. From 1.0 to 2.0 equivalents of Cd(II), the cross peak at 8.03 ppm appears that corresponds to perturbations of the H^N-H^{γ} of Glu21 resonance upon addition of Cd(II). From 1.5 to 2.0 equivalents of added Cd(II), a cross peak at 7.86 ppm appears which may represent the perturbation of the Cys30 resonance due to interaction of Cd(II) with the partially deprotonated Cys30 at pH 6.0. To ascertain that region **b** in Figure 7 represents the cross peaks due to Cd(II) binding to the Cys16 and not to the Cys30 site, a series of pH dependent NOESY experiments were performed. The pH of a solution containing 3.21 mM $(\text{GRANDL12AL16CL26AL30C})_3$ and 2.0 equivalents of Cd(II) was increased from 6.0 to 8.5 (Figure S6). With an increase in pH, two new cross peaks appear at 7.6 ppm (region **d**) and 7.93 ppm (region **e**). These resonances are assigned as $H^N_{16}-H^{\beta}_{16}$ for $[\text{Cd}(\text{II})(\text{H}_2\text{O})]_2(\text{GRANDL12AL16CL26AL30C})_3^{2-}$ (region **d**) and $H^N_{30}-H^{\beta}_{30}$ for $[\text{Cd}(\text{II})(\text{H}_2\text{O})]_2(\text{GRANDL12AL16CL26AL30C})_3^{2-}$ (region **e**). The cross peak at 7.81 ppm (region **b**) remains at high pH (8.5) indicating the presence of the species $[\text{Cd}(\text{II})(\text{H}_2\text{O})]^{16}[\text{apo}]^{30}(\text{GRANDL12AL16CL26AL30C})_3^{4-}$ in solution. This result demonstrates that the new cross peaks are associated with Cd(II) binding to the less acidic Cys30 site and that the cross peak at region **b** in Figure 7 results from Cd(II) binding to the more acidic Cys16 site.

Discussion

The objective of this study is to assess whether the position of metal sites along the linear sequence of the peptide influences, possibly fine-tuning, the physical properties of the bound metal ions. Secondly, we wanted to assess whether the presence of a second bound metal influenced the properties of the first coordinated metal. To address these issues, we designed peptides capable of binding two equivalents of Cd(II) with identical coordination geometries and evaluated the physical properties of the bound ions, the selectivity of the metals for the different sites and the influence of pH on the observed properties. While other studies have shown that *de novo* peptides can bind two metal ions in separate mononuclear sites^{52,53} or in binuclear centers,^{54–56} they did not address the question of selective binding of the same metal ion in different centers having distinct geometries. The model peptides used to test these issues are $\text{GRANDL12AL16CL26AL30C}$, designed to have two 4-coordinate sites (CdS_3O) and $\text{GRANDL16PenL19IL23PenL26I}$ with two 3-coordinate sites (CdS_3). Since these sites are located at different positions in the coiled coil, the final Cd(II) constructs perfectly evaluate how metal positioning influences their physical properties. Thus, we may assess whether or not Cd(II) displays site-selective binding, whether the binding of one metal in a helix alters the properties of the second metal and whether the spectral properties of a bound Cd(II) are dependent on the proximity to the center or ends of a helical bundle. These important issues are yet to be addressed with designed peptides.

Designing a Peptide With Dual 3-Coordinate Sites

Our first challenge was designing the sulfur substituted GRAND peptides. To guide our designs, we have used the linear correlation between the ^{113}Cd NMR and ^{111}mCd PAC spectroscopy.⁴² We began with the preparation of the peptide containing two 3-coordinate sites. Based on

our previous results, positions near the edge of the coiled coil should be avoided in order to obtain a 3-coordinate site.^{33,34,36} These positions are prone to coordinate water due to the fraying of the α -helices and thus, both binding sites should be buried in the interior of the coiled coil. The starting point for the design was our peptide $\text{GRANDL16PenL26AL30C}$ known to contain one 3-coordinate site and one 4-coordinate site (Figure 3, red).³⁶ Our first strategy was to keep the Pen residue in position 16, since we know this location generates a 3-coordinate site,³⁴ and introduce the second Pen as far as possible from the C-terminal edge to avoid fraying, but separate enough from the first one to avoid the disruption of this site. Based on these requisites, the second Pen could be introduced into position 23 (fourth heptad repeat); however, making a peptide containing two separate binding sites that can encapsulate two Cd(II) ions as 3-coordinate complexes at both the binding sites is not so straightforward as simply adding a Pen to an interior site as a construct previously synthesized in our group, $\text{GRANDL12AL16CL23Pen}$ (unpublished results) bound Cd(II) in position 23 as a mixture of species (55% CdS_3O and 45% CdS_3). Since moving the Pen towards the interior of the coiled coil could disrupt the first binding site, we decided to substitute Leu26 for an Ile. This residue is known to pack better and should prevent fraying by generating a more compact packing of the α -helices. The ^{113}Cd NMR spectra of the resulting construct, $\text{GRANDL16PenL23PenL26I}$, loaded with 2 equivalents of Cd(II) at pH 9.6 exhibited two distinct peaks, with chemical shifts of 678 and 666 ppm. These values revealed the disruption of the first Pen site (L16Pen) by the introduction of the second site (L23Pen) since a ^{113}Cd chemical shift of 685 ppm was observed for the original fully 3-coordinate 16Pen site.^{34,36} While the chemical shifts obtained represented an improvement towards the achievement of fully 3-coordinated sites, they indicate an equilibrium between CdS_3 and CdS_3O (678 ppm ~ 80:20 and 666 ppm ~ 71:29, Table 4). We have used the ^{113}Cd NMR shifts to assess the degree of formation of the CdS_3 , but this method could provide a slight underestimate of the amount present. The existence of a single Leu layer between these two sites seemed to be insufficient to keep a compact packing and avoid perturbation of the 16Pen site due to the presence of the 23Pen site. To improve these results and minimize the disruption of the 16Pen site, the Leu layer just below (Leu19) was replaced by Ile. This generates an even more compact packing of the hydrophobic core. Indeed, this strategy succeeded as $\text{GRANDL16PenL19IL23PenL26I}$ bound $2(\pm 0.14)$ equivalents of Cd(II) with trigonal planar CdS_3 geometries (686 ($\text{CdS}_3\text{:CdS}_3\text{O}$ ~ 87:13, Table 4) and 681 ($\text{CdS}_3\text{:CdS}_3\text{O}$ ~ 83:17, Table 4) ppm) as shown in Figure 3 (green).

Designing a Peptide With Dual 4-Coordinate Sites

Our starting point for designing the peptide containing two 4-coordinate sites was again the construct $\text{GRANDL16PenL26AL30C}$.³⁶ In this case, we kept the segment containing the 4-coordinate site (L26AL30C) and modified the L16Pen center, known to generate a 3-coordinate site,³⁴ to an L12AL16C center to obtain the second 4-coordinate site. Previous work with TRL12AL16C suggested that this would be a successful approach.³⁴ This design yields the final peptide $\text{GRANDL12AL16CL26AL30C}$. The binding of Cd(II) was characterized by ^{113}Cd NMR spectroscopy and the spectrum of the fully loaded $[\text{Cd(II)}(\text{H}_2\text{O})_2]_2(\text{GRANDL12AL16CL26AL30C})_3^{2-}$ showed two resonances at 589 ($\text{CdS}_3\text{:CdS}_3\text{O}$ ~ 8:92, Table 4) and 572 ($\text{CdS}_3\text{:CdS}_3\text{O}$ ~ 0:100, Table 4) ppm. These chemical shifts are consistent with those expected for a CdS_3O environment,⁴² demonstrating that we successfully designed a single peptide with two 4-coordinate centers.

$\text{GRANDL16PenL19IL23PenL26I}$ Peptide

a) Physical Properties—With the two desired **GRAND** peptides in hand, we next investigated the impact that the position of the centers has on the intrinsic physical properties of the metal ion. Titration of Cd(II) into a solution containing 60 μM (20 μM trimer) $\text{GRANDL16PenL19IL23PenL26I}$ at pH 9.5 was accompanied by an absorption increase

centered at 235 nm and a final extinction coefficient of $54,772 \text{ M}^{-1}\text{cm}^{-1}$, which is consistent with the formation of two Cd(II) tris thiolate chromophores. The titration curve shown in Figure 1 (green color) indicates that the stoichiometry of peptide to Cd(II) is $3:2(\pm 0.14)$ and, therefore, the best description for the Cd(II) complex formed under these conditions is $[\text{Cd}(\text{II})]_2(\text{GRANDL16PenL19IL23PenL26I})_3^{2-}$. As discussed above, based on the ^{113}Cd NMR spectrum (Figure 3, green) these two Cd(II) sites are trigonal CdS_3 . Further support for this assignment comes from the ^{111}mCd PAC spectrum of $[\text{Cd}(\text{II})]_2(\text{GRANDL16PenL19IL23PenL26I})_3^{2-}$ (Figure 6F). This dicadmium peptide has a high frequency signal (NQ11) with parameters $\omega_0 = 0.461(1) \text{ rad/ns}$ and $\eta = 0.02(4)$ (Table 3) that correspond to a trigonal planar CdS_3 geometry with highly similar structures, indicating that the two sites created in $(\text{GRANDL16PenL19IL23PenL26I})_3$ yield two metal ion sites with no indication of CdS_3O .

We have previously discriminated CdS_3 and CdS_3O sites in **TRI** and **GRAND** peptides by examining the pH profile for the formation of the tris cysteine complexes. In these cases the relevant equilibrium is: $[\text{Cd}(\text{pep})(\text{Hpep})_2]^+ \rightarrow [\text{Cd}(\text{pep})_3]^- + 2\text{H}^+$. We have found that CdS_3 complexes (using Pen or Cys) have effective pK_{a2} values that are far more basic than the comparable CdS_3O structures (e.g., TRI L16Pen , $\text{pK}_{a2}=15.8$ vs. TRI L12AL16C , $\text{pK}_{a2}=12.2$).⁴² The pH profile for the binding of the 2 equivalents of Cd(II) to this peptide (Figure 2) is consistent with these results since the pK_{a2} values obtained, 15.2 and 15.9, are very similar and quite basic as is expected for 3-coordinate sites. Based on previous observations, we infer that the site with the ^{113}Cd NMR shift of 686 ppm has the more basic of these pK_{a2} values as it has virtually no CdS_3O present. All of these data demonstrate that we have prepared a single peptide capable of binding two equivalents of Cd(II) with trigonal planar CdS_3 coordination. The fact that the physical properties observed for both sites are comparable indicates that the location of the 3-coordinate site in the coiled coil is not perturbing or fine-tuning its intrinsic properties. Furthermore, at this point it appears that in a well packed helix, the presence of the second CdS_3 center has minimal impact on the original chromophore (i.e., vs GRANDL16Pen). This latter point will now be addressed in more detail.

b) Does the Metallation State of One Site Perturb the Other Site?—Now we will focus on the two related experiments performed with the $\text{GRANDL16PenL19IL23PenL26I}$ peptide as shown in Figure 4. In the following section we will discuss the possible interpretations of the data presented in Figure 4A and 4B in a systematic way. We will refer to the site with chemical shift of 686 ppm as site A and the site with chemical shift of 681 ppm as site B. In case of the pH dependent ^{113}Cd NMR measurements presented in Figure 4A, the peptide is loaded with two equivalents of Cd(II) so that both sites are filled with metal. We have shown previously that the binding model for Cd(II) to these systems is that the metal first coordinates to the site of interest forming a $[\text{Cd}(\text{pep})(\text{Hpep})_2]^+$ species at low pH. As the pH is raised, two protons are released to give the tris thiolato complex $[\text{Cd}(\text{pep})_3]^-$. Thus, the two relevant peptide species under low pH conditions are $[\text{Cd}(\text{pep})(\text{Hpep})_2]^+$ and $[\text{Cd}(\text{pep})_3]^-$, while no apo peptide is present. Figure 4A shows that at low pH the 691 ppm peak dominates over the 681 ppm peak. With an increase in pH, the 681 ppm peak gains intensity over the 691 ppm peak and at pH 9.5 only the 681 (site B) and 686 (site A) ppm peaks are present. The 686 ppm peak gained intensity continuously during the course of the pH titration. The conversion from the 691 to the 681 ppm peak follows closely to the pK_{a2} determined for this peptide using UV-Vis spectroscopy (Table 2).

One interpretation of the data in Figure 4A suggests that the 691 ppm peak may arise from site B (681 ppm) when Cd(II) in site B is present as $[\text{Cd}(\text{pep})(\text{Hpep})_2]^+$ and disappears when all the Cd(II) is present as only $[\text{Cd}(\text{pep})_3]^-$ at site B. However, this model does not withstand the scrutiny of the data in Figure 4B. In this experiment all spectra are collected at

pH 9.5 which are conditions supporting only the $[\text{Cd}(\text{pep})_3]^-$ metal structure. In the presence of only 1.0 equivalent of Cd(II), we observe the simultaneous presence of both the peaks at 681 and 691 ppm. This observation suggests that the 691 ppm peak exists when the $[\text{Cd}(\text{pep})(\text{Hpep})_2]^+$ species at site B is absent. Therefore, considering the data in Figure 4A and 4B together, one can conclude that the 691 ppm peak cannot be an indicator of the presence of $[\text{Cd}(\text{pep})(\text{Hpep})_2]^+$ species at site B (681 ppm). Furthermore, the ^{113}Cd NMR resonance for $[\text{Cd}(\text{pep})(\text{Hpep})_2]^+$ has not been observed for a **TRI** peptide either as a dual site or mono site derivative,³ and if observable, would be predicted to be far up field of the $[\text{Cd}(\text{pep})_3]^-$ chemical shift region. Thus, we eliminate a monothiolate Cd(II) species as the origin of the 691 resonance.

A second possible interpretation of these data is that the 691 ppm peak is an alternative form of the 686 ppm peak which is a consequence of the partial occupancy of site B that gives rise to the 681 ppm peak. Data in Figure 4B are consistent with this idea as it shows that in the presence of 1 equivalent of $^{113}\text{Cd}(\text{II})$ at pH 9.5 (where all the Cd(II) is present as $[\text{Cd}(\text{pep})_3]^-$) indiscriminate binding is observed to both the Pen sites (681, 686 and 691 ppm). Subsequent changes upon addition of the second equivalent of the metal are also consistent with this interpretation. However, if we return to Figure 4A, which is collected under conditions where peptide is loaded with 2 equivalents of $^{113}\text{Cd}(\text{II})$ for all the spectra, we observe that the 691 peak appears at pH 7.5 through 8.2 even though site B (681 ppm) is fully occupied with Cd(II). Therefore, we conclude that the 691 ppm peak cannot be an alternate form of the 686 ppm peak when site B is unoccupied because in these experiments (Figure 4A) site B is always filled.

Thus, we believe the model that best explains both the data in Figure 4A and 4B is that the 691 ppm peak is a form of the 681 ppm peak and exists when site A (686 ppm) is either unfilled (metal titration, apo) or present with only one deprotonated sulfur (pH titration, $[\text{Cd}(\text{pep})(\text{Hpep})_2]^+$). Furthermore, the 681 ppm feature only occurs when site A has a fully formed trigonal Cd(II) structure ($[\text{Cd}(\text{pep})_3]^-$). Of course, the 681 and 686 ppm signals gain intensity as the pH is raised (Figure 4A) as a higher proportion of $[\text{Cd}(\text{pep})_3]^-$ is formed in both the sites; however, the 681 specie dominates over the specie giving rise to the 691 ppm signal as all of the Cd(II) in site A becomes $[\text{Cd}(\text{pep})_3]^-$ with increasing pH. Thus, the critical factor controlling the 10 ppm upfield shift of the ^{113}Cd NMR resonance is whether the final two thiolate sulfur atoms insert into the coordination sphere of the metal in site A. Hence, the 691 signal can appear either because an apo structure (present at high pH under substoichiometric conditions, Figure 4B) or a $[\text{Cd}(\text{pep})(\text{Hpep})_2]^+$ (present at lower pH under stoichiometric conditions, Figure 4A) structure occurring at site A (686 ppm). Recognizing this duality, it becomes clear that the switch between the 691 and 681 resonances is the rearrangement of the Pen side chains and subsequent structural/conformational change on going from an apo or partially bound $[\text{Cd}(\text{pep})(\text{Hpep})_2]^+$ form to the final $[\text{Cd}(\text{pep})_3]^-$ structure. Such an explanation is consistent with X-ray structures of related systems that have recently appeared.^{30,57,58} It can be concluded from the discussion of this section that the two sites in $_{\text{GRAND}}\text{L16PenL19IL23PenL26I}$ peptide are not completely independent of each other as Cd(II) bound to one of the sites (site B, 681 ppm) is perturbed by the metallation state (apo or $[\text{Cd}(\text{pep})(\text{Hpep})_2]^+$ or $[\text{Cd}(\text{pep})_3]^-$) of the second center (site A, 686 ppm). Site A, on the other hand, seems to be insensitive to the metallation state of site B, based on the data presented in Figure 4A and 4B. Of course one can hypothesize that site A is also being perturbed by the metallation state of site B and the resulting ^{113}Cd NMR signal(s) may be hidden under other peaks. However, based on the present data no definite conclusion can be drawn regarding this possibility. Table 5 summarizes these conclusions derived from Figures 4A and 4B. Taking into consideration our previous designs of disubstituted peptides,^{35,36,52} two layers of intervening Leu seem to be necessary to keep

both metal centers completely independent. In the peptide $\text{GRANDL16PenL19IL23PenL26I}$ there is only one intervening layer, Ile in this specific case, between both Cd(II) sites.

$\text{GRANDL12AL16CL26AL30C}$ Peptide

a) Physical Properties—With the $\text{GRANDL16PenL19IL23PenL26I}$ system well understood, we moved our attention to a peptide that should encapsulate two CdS_3O centers. The titration curve (Figure 1, blue color) following the binding of Cd(II) to $\text{GRANDL12AL16CL26AL30C}$ is consistent with the complexation of $2(\pm 0.14)$ equivalents of Cd(II) per trimer. The best description for the Cd(II) complex in this case is $[\text{Cd}(\text{II})(\text{H}_2\text{O})]_2(\text{GRANDL12AL16CL26AL30C})_3^{2-}$. This fully formed Cd(II) species has an extinction coefficient of $39,766 \text{ M}^{-1}\text{cm}^{-1}$ at 235 nm, which is lower than those of $[\text{Cd}(\text{II})]_2(\text{GRANDL16PenL19IL23PenL26I})_3^{2-}$ (Figure 1, green color) and $[\text{Cd}(\text{II})]^{16}[\text{Cd}(\text{II})(\text{H}_2\text{O})]^{30}(\text{GRANDL16PenL26AL30C})_3^{2-}$ (Figure 1, red color) and, therefore, consistent with having two 4-coordinate sites.^{34,36} To verify that both Cd(II) ions bind to the peptide $\text{GRANDL12AL16CL26AL30C}$ as a 4-coordinate CdS_3O species, we carried out ^{111}mCd PAC spectroscopic studies. The ^{111}mCd PAC spectrum obtained under conditions that favored full loading of the peptide Cd(II), showed two different NQIs, namely NQI2 and NQI3, in addition to NQI4 that is present in almost all the spectra (Figure 6G). This result indicates the presence of different Cd(II) species on the ^{111}mCd PAC timescale. The parameters for NQI2 ($\omega_0 = 0.342(6) \text{ rad/ns}$ and $\eta = 0.148(8)$, Table 3) are very similar to those observed for TRI12AL16C and has been assigned to a distorted tetrahedral CdS_3O species where the metal ion is most likely coordinated above the plane of the β -methylene protons of the Cys in an *exo* configuration, with an exogenous water molecule as a fourth ligand towards the N-terminus.^{34,42} The lower frequency NQI3 signal ($\omega_0 = 0.242(8) \text{ rad/ns}$ and $\eta = 0(1)$, Table 3) has parameters similar to those reported for the peptide TRI16CL19A which presents a water-binding pocket below the metal binding site.⁴² This peptide contains a 100% CdS_3O species and our best interpretation for this result is that Cd(II) is bound below the thiolate plane in an *endo* configuration with the water towards the C-terminus. This coordination geometry would resemble the one observed in the X-ray structure of $\text{As}(\text{csL9C})_3^{30}$ (Coil-Ser (CS) is a crystallizable analogue of **TRI** family of peptides)⁵⁹ where As(III) is bound to the three Cys sulfurs below the plane defined by their β -methylene protons and the lone pair pointing towards the C-terminus. For Cd(II), the water molecule, as the fourth coordinating ligand, replaces the lone pair of electrons. The *endo* configuration could be favored for TRI16CL19A because the generated hole lies just below the Cys. In contrast, the designed cavities for $\text{GRANDL12AL16CL26AL30C}$ are located above the Cys sulfur plane; however, the Cys30 is located far towards the C-terminus of the peptide where helical fraying of the coiled coil is significant. This fraying should generate a more promiscuous binding center that would allow the water to enter from the C-terminal direction and coordinate to Cd(II). The NQI3 signal has never been observed for peptides containing the Cys at position 16 and which are capable of binding Cd(II) as a 100% CdS_3O species with an *exo* configuration (TRI12AL16C , TRI12AL16Pen and TRI9AL16C).⁴² This observation suggests that in $\text{GRANDL12AL16CL26AL30C}$, NQI3 corresponds to the C-terminal binding site of L26AL30C. The corresponding monosubstituted peptide, GRANDL26AL30C , showed essentially the same two NQIs (NQI2 and NQI3) (Figure 6B). Indeed, the amplitude corresponding to the NQI2 signal was smaller than that obtained for $\text{GRANDL12AL16CL26AL30C}$ as would be expected since the peptide GRANDL26AL30C is missing the L12AL16C center (Table 3). Furthermore, the heterochromic peptide $\text{GRANDL16PenL26AL30C}$ showed the same three NQI signatures which were observed under conditions where the peptide was in excess compared to Cd(II) (ratio peptide/Cd(II) = 12/1). This heterochromic peptide is known to bind Cd(II) in the L26AL30C center selectively both at low and high pH values (Figure 6C and 6D; Table 3).³⁶ This result supports the assignment that the L26AL30C center binds Cd(II) as a mixture

of CdS_3O species, NQI2 and NQI3, best interpreted as to an *exo* and an *endo* configuration, respectively.

Once verified that the peptide $\text{GRANDL12AL16CL26AL30C}$ binds $2(\pm 0.14)$ equivalents of Cd(II) as 4-coordinate CdS_3O structures, we next investigated the pH dependence associated with this binding. The obtained pH titration curve (Figure 1, color blue) reveals that the second and third thiolates of this peptide bind to Cd(II) at lower pH values than those of the peptide $\text{GRANDL16PenL19IL23PenL26I}$. This observation is consistent with having 4-coordinate sites;⁴² however, the $\text{p}K_{\text{a}2}$ values obtained, 11.8 and 13.9, are not as similar to each other as those observed for Cd(II) binding to $\text{GRANDL16PenL19IL23PenL26I}$ (15.2 and 15.9). This is an interesting result since both sites are defined by the same type of residues and Cd(II) binds to both as CdS_3O species, as shown by ^{113}Cd NMR and ^{111}mCd PAC spectroscopy. More importantly, these values are different from those obtained for the coordination of Cd(II) to the peptides GRANDL12AL16C ($\text{p}K_{\text{a}2} = 11.3$)³⁴ and GRANDL26AL30C ($\text{p}K_{\text{a}2} = 9.9$)^{36,42}, each containing only one binding site (Figure 2). Indeed, the simulated pH profile for two equivalents of Cd(II) binding to $\text{GRANDL12AL16CL26AL30C}$ with the $\text{p}K_{\text{a}2}$ values of the individual sites (11.3 and 9.9) is quite different from the experimentally observed pH profile (Figure S7). Upon closer examination of these data, one realizes that one of the $\text{p}K_{\text{a}2}$ values (11.8) is close to the $\text{p}K_{\text{a}2}$ value of Cd(II) binding to GRANDL12AL16C . Assigning the value of 11.8 to the $\text{p}K_{\text{a}2}$ of Cd(II) binding to the site L12AL16C will imply that Cd(II) coordinates to the L26AL30C center with a $\text{p}K_{\text{a}2}$ of 13.9. This represents a difference of 4 log units between having this binding site in $\text{GRANDL12AL16CL26AL30C}$ vs GRANDL26AL30C and $\text{GRANDL16PenL26AL30C}$. The peptide $\text{GRANDL16PenL26AL30C}$ is known to coordinate Cd(II) in the 4-coordinate site with a $\text{p}K_{\text{a}2}$ of 9.6.³⁶

b) Assignment of Individual $\text{p}K_{\text{a}2}$ Values—At this point, it became essential to use NMR spectroscopy to assign the binding sites corresponding to these different $\text{p}K_{\text{a}2}$ values. We first carried out ^{113}Cd NMR pH titrations. Two important observations can be inferred from the spectra shown in Figure 5. First, that the binding site with a ^{113}Cd chemical shift of 572 ppm binds Cd(II) at lower pH values than the site with a ^{113}Cd chemical shift of 589 ppm. Second, in contrast to $\text{GRANDL16PenL19IL23PenL26I}$ (Figure 4A), the two binding centers in $\text{GRANDL12AL16CL26AL30C}$ are independent of each other since additional ^{113}Cd chemical shifts were not observed for the half-loaded peptides. In this peptide, the two Cys sites are separated by two Leu layers (19 and 23), in addition to the Ala26 layer, and this can explain this different behavior. Comparing the resonances at 572 ppm and 589 ppm with those observed for the complexes $[\text{Cd(II)(H}_2\text{O)}](\text{GRANDL12AL16C})_3^-$ (572 ppm)⁴² and $[\text{Cd(II)(H}_2\text{O)}](\text{GRANDL26AL30C})_3^-$ (588 ppm)³⁶, one is tempted to assign the Cd(II) binding $\text{p}K_{\text{a}2}$ values of 11.9 and 13.8 to L12AL16C and L26AL30C sites of the peptide $\text{GRANDL12AL16CL26AL30C}$, respectively.

To confirm these assignments, we directly monitored the ^1H chemical shifts of both Cys sites (Cys16 and Cys30) upon addition of Cd(II) . Two-dimensional NOESY and TOCSY ^1H NMR spectroscopy were employed to assign the backbone resonances of the peptide (Figure S5). This information was used to identify the resonances of the β -methylene protons (H^β) of each Cys. Subsequently, ^1H - ^1H NOESY experiments were carried out to monitor the binding of Cd(II) to Cys16 and Cys30 by observing the effects on resonances of the H^β protons. If the assignments based on ^{113}Cd NMR spectroscopy are correct, the sequential additions of 0.5 equivalents of $^{113}\text{Cd}(\text{NO}_3)_2$ up to a total of 2 equivalents at pH 6.0 should cause changes mainly in the region of the spectrum corresponding to the H^N - H^β cross peak of Cys16. Figure 7 demonstrates that this indeed happens. A new major cross peak appears at 7.81 ppm (region b) that corresponds to the perturbation of the two individual H^β resonances of Cys16 upon coordination of Cd(II) to this residue. These results indicate that

at pH 6.0 Cd(II) binds primarily to Cys16 forming the species $[\text{Cd}(\text{II})(\text{H}_2\text{O})]^{16}[\text{apo}]^{30}(\text{GRANDL12AL16CL26AL30C})_3^-$.

We further validated this assignment by carrying out a ^{113}Cd NMR spectrum of a solution containing 3.3 mM $(\text{GRANDL12AL16CL26AL30C})_3$ and 1.0 equivalent of $^{113}\text{Cd}(\text{NO}_3)_2$ at pH 6.0. This spectrum shows a single resonance at 572 ppm (Figure S3) that corresponds to Cd(II) bound to the L12AL16C site. Next, we performed a pH dependent NOESY experiment in the presence of two equivalents of $^{113}\text{Cd}(\text{NO}_3)_2$ (Figure S6) and used this information for the assignment. The discussion related to the rest of the assignment section can be found in the Supporting Information. The combination of the UV-Vis, ^{113}Cd NMR and ^1H NMR spectroscopic data supports the conclusion that Cd(II) binds to the L12AL16C site with a $\text{pK}_{\text{a}2}$ value of 11.8 and to the L26AL30C site with a $\text{pK}_{\text{a}2}$ value of 13.9. In addition, these results have revealed a dynamic behavior of the L26AL30C site. The origin of this dynamic nature is not yet completely clear. However, the close proximity of this site to the edge of the α -helix, where fraying of the helices in the coiled coil is an important factor, could promote this situation. Indeed, ^{111}mCd PAC spectroscopy shows how all the peptides containing the L26AL30C site display a mixture of NQI2, NQI3, and NQI4 (minor fraction), suggesting structural variability, whereas the L12AL16C only displays the NQI2. Despite this different behaviour, the ^{113}Cd NMR spectrum (Figure S4) observed after addition of one equivalent of $^{113}\text{Cd}(\text{NO}_3)_2$ to a solution containing $(\text{GRANDL12AL16CL26AL30C})_3$ at pH 8.5 shows Cd(II) coordination to both sites. Thus, Cd(II) does not show selectivity for either site at pH values where CdS_3O should fully exist in this peptide, as was observed for the CdS_3 centers in $[\text{Cd}(\text{II})]_2(\text{GRANDL16PenL19IL23PenL26I})_3^{2-}$.

c) Possible Reasons for the $\text{pK}_{\text{a}2}$ Differences—The $\text{pK}_{\text{a}2}$ value of $[\text{Cd}(\text{II})(\text{H}_2\text{O})](\text{GRANDL12AL16C})_3^-$ is 11.3 and the L12AL16C site of $[\text{Cd}(\text{II})(\text{H}_2\text{O})]_2(\text{GRANDL12AL16CL26AL30C})_3^{2-}$ is 11.8. The shift between these two values is relatively minor and requires little additional comment. However, the nearly 4 unit higher $\text{pK}_{\text{a}2}$ of the L26AL30C site (13.9) in the $\text{GRANDL12AL16CL26AL30C}$ peptide as compared to $[\text{Cd}(\text{II})(\text{H}_2\text{O})](\text{GRANDL26AL30C})_3^-$ (9.9) deserves further consideration. **GRAND** peptides, by virtue of the additional heptad, are significantly more stable than the **TRI** peptides. Each substitution of Cys or Ala for Leu causes a marked disruption of this stabilizing hydrophobic layer in either series. The **GRAND** peptides have 10 Leu layers (Table 1); however, in $\text{GRANDL12AL16CL26AL30C}$, four of these Leu layers have been modified causing as much as a 16–20 kcal/mol destabilization from the parent **GRAND** three stranded coiled coil.²⁷ Similarly, an 8–10 kcal/mol difference occurs between $\text{GRANDL12AL16CL26AL30C}$ and a single site analogue (e.g., GRANDL12AL16C). Because the packing around the centrally located metal site L12AL16C should be only slightly destabilized by this overall decrease in free energy of association by adding the L26AL30C site, a small shift in $\text{pK}_{\text{a}2}$ from 11.3 to 11.8 is reasonable. However, the L26AL30C is very close to the C-terminus, which already is expected to suffer from significant fraying.^{30,57–59} The entire coiled coil is destabilized going from GRANDL26AL30C to $\text{GRANDL12AL16CL26AL30C}$, especially by disrupting the center of the assembly. One might expect that this alteration could significantly perturb metal binding in the L26AL30C position, which is the inherently less stable site. One can envision that making a more stable aggregate by conferring improved packing at the C-terminus end of the $\text{GRANDL12AL16CL26AL30C}$ peptide would shift the $\text{pK}_{\text{a}2}$ values back towards more acidic range. To test this hypothesis we designed the construct $\text{GRANDL12AL16CL26AL30CL33I}$ where Leu33 at the C-terminus end has been replaced by Ile which is known to render better packing. The resulting $\text{pK}_{\text{a}2}$ values for this new construct are 11.6 and 13.5, respectively (Table 2, Figure 2 purple). The shift in $\text{pK}_{\text{a}2}$ for the two sites of this new peptide is minor (0.2 and 0.4) from the parent $\text{GRANDL12AL16CL26AL30C}$ peptide and is within the error of measurements. To understand the intricate interplay

between peptide stabilities and the resulting pK_{a2} values, we analyzed the stability of the unmetallated GRANDL12AL16C, GRANDL26AL30C, GRANDL12AL16CL26AL30C and GRANDL12AL16CL26AL30CL33I coiled coils using circular dichroism spectroscopy and guanidinium hydrochloride (GuHCl) denaturation titrations (Figure S2).

These experiments illustrate a significant decrease in stability of the GRANDL12AL16CL26AL30C construct as compared to the single site peptides GRANDL12AL16C and GRANDL26AL30C. Because of only minor shift in the pK_{a2} value of GRANDL12AL16CL26AL30CL33I from GRANDL12AL16CL26AL30C and due to the fact that the stability of the GRANDL12AL16CL26AL30CL33I construct could not be quantified, the relationship between pK_{a2} and aggregate stability could not be established. Understanding the intricate interplay between coiled coil stability and pK_{a2} would require future studies with many more protein constructs. However, we can qualitatively say that the explanation for the 4 unit shift in pK_{a2} between GRANDL26AL30C and GRANDL12AL16CL26AL30C is, in part due to the general destabilization of the coiled coil by the addition of the second metal binding site at the middle of the peptide scaffold as it resulted in a significant destabilization of the coiled coil as observed by GuHCl denaturation studies. As a final note, preparing the dual CdS₃ construct GRANDL16PenL19IL23PenL26I from the parent GRANDL16Pen peptide is more tolerant to mutations because in this case, all of the residues replacing Leu (Pen or Ile) confer greater stability to the aggregate; however, one should recognize that to achieve such a dual 3-coordinate peptide still required the addition of a heptad (**TRI** to **GRAND**) and the incorporation of Ile for Leu.

Conclusions

In this article we have investigated how the position of two metal binding sites that have “identical” first coordination environments within the three stranded α -helical coiled coils, can fine-tune the physical properties of bound metal ions [in this case, Cd(II)]. The peptide GRANDL16PenL19IL23PenL26I, having a more rigid structure, binds two Cd(II) ions as trigonal planar 3-coordinate CdS₃ structures. Even though the physical properties of the two sites in this peptide are similar, these two sites are not completely independent of each other. The metallation state (apo or [Cd(pep)(Hpep)₂]⁺ or [Cd(pep)₃]⁻) of one site perturbed the Cd(II) bound to the second site. We found that a minimum of two Leu layers are required to keep both metal centers completely independent. The GRANDL12AL16CL26AL30C peptide, that binds two Cd(II) ions as pseudotetrahedral 4-coordinate CdS₃O structures, shows a distinct behavior and displays different physical properties for the two metal sites. The pK_{a2} values, corresponding to the equilibrium [Cd(pep)(Hpep)₂]⁺ $\rightarrow$ [Cd(pep)₃]⁻ + 2H⁺, range from 9.9 to 13.9, and the L26AL30C site shows dynamic behavior, which is not observed for the L12AL16C site. This is the combined effect of several factors playing a crucial role in determining the final properties of the bound Cd(II), among them, are the packing of the adjacent Leu residues, size of the intended cavity (*endo* vs. *exo*) and location of the binding centers along the coiled coils. Thus, one can not define a location simply as a “4-coordinate” site without being cognizant of the numerous factors that determine the final physical properties of these types of structures.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Dr. Eugenio Alvarado for his assistance in performing the 2D NMR experiments. V.L.P. thanks the National Institute of Health for support of this research (ES012236) O.I. thanks the Margaret and Herman Sokol

Foundation for a Postdoctoral Award. L.H. thanks the Danish Research Council for Independent research – Natural Sciences for support.

References

1. DeGrado WF, Summa CM, Pavone V, Nistri F, Lombardi A. *Annu. Rev. Biochem.* 1999; 68:779–819. [PubMed: 10872466]
2. Gibney B, Rabanal F, Dutton P. *Current Opinion In Chemical Biology.* 1997; 1:537–542. [PubMed: 9667893]
3. Peacock AFA, Iranzo O, Pecoraro VL. *Dalton Transactions.* 2009;2271–2280. [PubMed: 19290357]
4. Lu Y, Yeung N, Sieracki N, Marshall NM. 2009; 460:855–862.
5. Iranzo O, Ghosh D, Pecoraro VL. *Inorg. Chem.* 2006; 45:9959–9973. [PubMed: 17140192]
6. Gibney BR, Rabanal F, Skalicky JJ, Wand AJ, Dutton PL. *J. Am. Chem. Soc.* 1999; 121:4952–4960.
7. Gibney BR, Dutton PL. *Adv. Inorg. Chem, Vol 51.* 2001; 51:409–455.
8. Reedy CJ, Gibney BR. *Chem. Rev.* 2004; 104:617–649. [PubMed: 14871137]
9. Zhuang J, Amoroso JH, Kinloch R, Dawson JH, Baldwin MJ, Gibney BR. *Inorg. Chem.* 2004; 43:8218–8220. [PubMed: 15606161]
10. Kennedy ML, Petros AK, Gibney BR. *J. Inorg. Biochem.* 2004; 98:727–732. [PubMed: 15134918]
11. Cochran FV, Wu SP, Wang W, Nanda V, Saven JG, Therien MJ, DeGrado WF. *Journal of the American Chemical Society.* 2005; 128:663.
12. McAllister KA, Zou H, Cochran FV, Bender GM, Senes A, Fry HC, Nanda V, Keenan PA, Lear JD, Saven JG, Therien MJ, Blasie JK, DeGrado WF. *Journal of the American Chemical Society.* 2008; 130:11921–11927. [PubMed: 18710226]
13. Ghirlanda G, Osyczka A, Liu W, Antolovich M, Smith KM, Dutton PL, Wand AJ, DeGrado WF. *Journal of the American Chemical Society.* 2004; 126:8141–8147. [PubMed: 15225055]
14. Nistri F, Lombardi A, D'Andrea LD, Sanseverino M, Maglio O, Pavone V. *Peptide Science.* 1998; 47:5–22. [PubMed: 9692324]
15. Sakamoto SOI, Ueno A, Mihara H. *J. Chem. Soc., Perkin Trans.* 1999; 2:2059–2069.
16. Obataya I, Kotaki T, Sakamoto S, Ueno A, Mihara H. *Bioorganic & Medicinal Chemistry Letters.* 2000; 10:2719–2722. [PubMed: 11133076]
17. Calhoun JR, Nistri F, Maglio O, Pavone VAL, DeGrado WF. *Peptide Sci.* 2005; 80:264–278.
18. Geremia S, DiCostanzo L, Randaccio L, Engel DE, Lombardi A, Nistri F, DeGrado WF. *J. Am. Chem. Soc.* 2005; 127:17266–17276. [PubMed: 16332076]
19. Kharenko OA, Ogawa MY. *J. Inorg. Biochem.* 2004; 98:1971–1974. [PubMed: 15522423]
20. Kharenko OA, Kennedy DC, Demeler B, Maroney MJ, Ogawa MY. *J. Am. Chem. Soc.* 2005; 127:7678–7679. [PubMed: 15913348]
21. Li XQ, Suzuki K, Kanaori K, Tajima K, Kashiwada A, Hiroaki H, Kohda D, Tanaka T. *Protein Sci.* 2000; 9:1327–1333. [PubMed: 10933497]
22. Suzuki K, Hiroaki H, Kohda D, Nakamura H, Tanaka T. *J. Am. Chem. Soc.* 1998; 120:13008–13015.
23. Kiyokawa T, Kanaori K, Tajima K, Koike M, Mizuno T, Oku J, Tanaka T. *J. Pept. Res.* 2004; 63:347–353. [PubMed: 15102052]
24. Shiga D, Nakane D, Inomata T, Masuda H, Oda M, Noda M, Uchiyama S, Fukui K, Takano Y, Nakamura H, Mizuno T, Tanaka T. *Biopolymers.* 2009; 91:907–916. [PubMed: 19598226]
25. Ghosh D, Pecoraro VL. *Inorg. Chem.* 2004; 43:7902–7915. [PubMed: 15578824]
26. Farrer B, Pecoraro VL. *Proc. Natl. Acad. Sci., U.S.A.* 2003; 100:3760–3765. [PubMed: 12552128]
27. Dieckmann GR, McRorie DK, Lear JD, Sharp KA, DeGrado WF, Pecoraro VL. *J. Mol. Biol.* 1998; 280:897–912. [PubMed: 9671558]
28. Dieckmann GR, McRorie DK, Tierney DL, Utschig LM, Singer CP, O'Halloran TV, Penner-Hahn JE, DeGrado WF, Pecoraro VL. *J. Am. Chem. Soc.* 1997; 119:6195–6196.

29. Farrer BT, Harris NP, Balchus KE, Pecoraro VL. *Biochemistry*. 2001; 40:14696–14705. [PubMed: 11724584]
30. Touw DS, Nordman CE, Stuckey JA, Pecoraro VL. *Proc. Natl. Acad. Sci., U.S.A.* 2007; 104:11969–11974. [PubMed: 17609383]
31. Luczkowski M, Stachura M, Schirf V, Demeler B, Hemmingsen L, Pecoraro VL. *Inorganic Chemistry*. 2008; 47:10875–10888. [PubMed: 18959366]
32. Matzapetakis M, Farrer BT, Weng T-C, Hemmingsen L, Penner-Hahn JE, Pecoraro VL. *J. Am. Chem. Soc.* 2002; 124:8042–8054. [PubMed: 12095348]
33. Lee KH, Matzapetakis M, Mitra S, Marsh ENG, Pecoraro VL. *J. Am. Chem. Soc.* 2004; 126:9178–9179. [PubMed: 15281796]
34. Lee K-H, Cabello C, Hemmingsen L, Marsh ENG, Pecoraro VL. *Angew. Chem., Int. Ed.* 2006; 45:2864–2868.
35. Peacock AFA, Hemmingsen L, Pecoraro VL. *Proceedings of the National Academy of Sciences*. 2008; 105:16566–16571.
36. Iranzo O, Cabello C, Pecoraro VL. *Angew. Chem., Int. Ed.* 2007; 46:6688–6691.
37. DeLano, WL. The PyMOL Molecular Graphics System, DeLano Scientific, Palo Alto, California, USA. 2005. <http://www.pymol.org>.
38. **Nomenclature:** While previously describing in detail the nomenclature for peptide modifications, we have not fully provided descriptors for metal complexation to these peptides. We will provide these definitions here with respect to Cd(II) and the exogenous ligand water; however, the nomenclature is general for any metal or non-protein bound ligand. We refer to an "apo peptide" as one which does not have metal in the designed metal coordination site within the hydrophobic interior of the coiled coils. We do not refer to an "apo peptide" to represent situations without the presence of any cofactors. Metals that may be bound non-specifically to the exterior hydrophilic residues are not considered to be metallated proteins/peptides in this context. Cd(II)(TRIL16C)₃[−] indicates that Cd(II) is bound to the three stranded coiled coil; however, the metal coordination environment is either unknown or is a mixture of species (e.g., Cd(II)(TRIL16C)₃[−] contains a 55:45 mixture of CdS₃O and CdS₃, respectively). When the metal is placed within brackets, as in [Cd(II)(H₂O)](TRIL12AL16C)₃[−], we specify the coordination environment (in this case CdS₃O) and the possible exogenous ligand (here water). If the site has only protein ligands, then it would be represented as [Cd(II)](TRIL16Pen)₃[−]. At low pH, one can encounter the situation where the cysteine sulfurs are protonated and may, or may not, be directly coordinated to the metal. In this case, we indicate this situation as [Cd(II)](TRIL16Pen[S,(SH)₂])₃[−] in which one cysteine is bound as a thiolate and the remaining two cysteines are protonated. When a peptide contains more than one binding site, we use the above nomenclature, but specify which site is being discussed by adding a superscript outside of the bracket to indicate the amino acid residues coordinating the specific metal (e.g., [Cd(II)]¹⁶[Cd(II)(H₂O)]³⁰(GRANDL16PenL26AL30C)₃^{−2}). Finally for cases where dual site peptides exhibit specificity for metal complexation, we will utilize [apo] to designate an empty site (e.g., [apo]¹⁶[Cd(II)(H₂O)]³⁰(GRANDL16PenL26AL30C)₃[−]).
39. Chan, WC.; White, PD. *Fmoc Solid Phase Peptide Synthesis: A Practical Approach*. New York: Oxford Univ. Press; 2000.
40. Mantle M, Stewart G, Zayas G, King M. *Biochem. J.* 1990; 266:597–604. [PubMed: 2317206]
41. Matzapetakis M, Ghosh D, Weng T-C, Penner-Hahn JE, Pecoraro VL. *J. Biol. Inorg. Chem.* 2006; 11:876–890. [PubMed: 16855818]
42. Iranzo O, Jakusch T, Lee K-H, Hemmingsen L, Pecoraro VL. *Chemistry - A European Journal*. 2009; 15:3761–3772.
43. Pace, CN.; Scholtz, JM. *Protein Structure: A Practical Approach*. Oxford: Oxford University Press; 1997.
44. Boice JA, Dieckmann GR, Degrado WF, Fairman R. *Biochemistry*. 1996; 35:14480–14485. [PubMed: 8931544]
45. Cobas, C.; Cruces, J.; Sardina, FJ. 2.3 ed. Spain: Universidad de Santiago de Compostela; 2000.
46. Jeener J, Meier BH, Bachmann P, Ernst RR. *Journal of Chemical Physics*. 1979; Vol. 71
47. Hoult DI. *Journal of Magnetic Resonance*. 1976; Vol. 21
48. Rance M. *Journal of Magnetic Resonance*. 1987; Vol. 74

49. MestReNova; X ed. Santiago de Compostela. Spain: 2009.
50. Hemmingsen L, Bauer R, Bjerrum MJ, Zeppezauer M, Adolph HW, Formicka G, Cedergren-Zeppezauer E. *Biochemistry*. 1995; 34:7145–7153. [PubMed: 7766625]
51. Hemmingsen LBR, Bjerrum M, Adolph H, Zeppezauer M, Cedergren-Zeppezauer E. *Eur. J. Biochem.* 1996; 241:546–551. [PubMed: 8917454]
52. Matzapetakis M, Pecoraro VL. *J. Am. Chem. Soc.* 2005; 127:18229–18233. [PubMed: 16366576]
53. Tanaka T, Mizuno T, Fukui S, Hiroaki H, Oku J-i, Kanaori K, Tajima K, Shirakawa M. *J. Am. Chem. Soc.* 2004; 126:14023–14028. [PubMed: 15506765]
54. Lombardi A, Summa CM, Geremia S, Randaccio L, Pavone V, DeGrado WF. *Proc. Natl. Acad. Sci., USA*. 2000; 97:6298–6305. [PubMed: 10841536]
55. Summa CM, Rosenblatt MM, Hong J-K, Lear JD, DeGrado WF. *J. Mol. Biol.* 2002; 321:923–938. [PubMed: 12206771]
56. Spiegel K, De Grado WF, Klein ML. *Proteins: Struct., Funct., and Bioinf.* 2006; 65:317–330.
57. Peacock AFA, Stuckey JA, Pecoraro VL. *Angewandte Chemie International Edition*. 2009; 48:7371–7374.
58. Chakraborty S, Touw DS, Peacock AFA, Stuckey JA, Pecoraro VL. *Journal of the American Chemical Society*. 2010 *accepted*.
59. Lovejoy B, Choe S, Cascio D, McRorie D, DeGrado W, Eisenberg D. *Science*. 1993; 259:1288–1293. [PubMed: 8446897]

Figure 1.

Titration curves obtained by plotting the change in the absorbance at 235 nm as a function of the equivalents of CdCl_2 added to solutions containing 20 μM ($\text{GRANDL16PenL26AL30C}$)₃ at pH 9.0 (red), 20 μM ($\text{GRANDL12AL16CL26AL30C}$)₃ at pH 8.6 (blue) and 20 μM ($\text{GRANDL16PenL19IL23PenL26I}$)₃ at pH 9.5 (green). All the curves plateau at 2 ± 0.14 equivalents of CdCl_2 per equivalent of peptide trimer.

Figure 2.
pH dependence of the binding of 2 equivalents of CdCl_2 to $20 \mu\text{M}$ $(\text{GRANDL16PenL26AL30C})_3$ (red), $(\text{GRANDL12AL16CL26AL30C})_3$ (blue), $(\text{GRANDL16PenL19IL23PenL26I})_3$ (green), $(\text{GRANDL12AL16CL26AL30CL33I})_3$ (purple) and of 1 equivalent of Cd(II) to $20 \mu\text{M}$ $(\text{GRANDL26AL30C})_3$ (black), $(\text{GRANDL12AL16C})_3$ (orange) and $(\text{GRANDL16Pen})_3$ (magenta). UV/Vis absorbance due to LMCT band at 235 nm was monitored during the course of titration and is plotted as normalized absorbance vs. pH.

Figure 3. ^{113}Cd NMR spectra of 3.0 mM $[\text{Cd}(\text{II})]^{16}[\text{Cd}(\text{II})(\text{H}_2\text{O})]^{30}(\text{GRANDL16PenL26AL30C})_3^{2-}$ at pH 9.6 (red), 3.4 mM $[\text{Cd}(\text{II})]_2(\text{GRANDL16PenL19IL23PenL26I})_3^{2-}$ at pH 9.5 (green) and 3.3 mM $[\text{Cd}(\text{II})(\text{H}_2\text{O})]_2(\text{GRANDL12AL16CL26AL30C})_3^{2-}$ at pH 8.5 (blue). Ball and stick models show the coordination environments of 3- and 4-coordinate Cd(II) complexes. Yellow spheres represent S atoms of Cys/Pen with the green and red spheres representing Cd(II) ion and water molecule, respectively.

Figure 4. ^{113}Cd NMR spectra of solutions containing (A) 3.0 mM $(\text{GRANDL16PenL19IL23PenL26I})_3$ and 2 equivalents of $^{113}\text{Cd}(\text{NO}_3)_2$ at different pH values, and (B) 3.3 mM $(\text{GRANDL16PenL19IL23PenL26I})_3$ loaded with 1 and 2 equivalents of $^{113}\text{Cd}(\text{NO}_3)_2$ at pH 9.5.

Figure 5. ^{113}Cd NMR spectra of solutions containing 3.3 mM $(\text{GRANDL12AL16CL26AL30C})_3$ and 2 equivalents of $^{113}\text{Cd}(\text{NO}_3)_2$ at different pH values. (The most downfield peak marked by star is an impurity).

Figure 6.

^{111}mCd PAC spectra of the different **GRAND** peptides [Fourier transform: experimental data (thin line) and fits (bold faced line) are shown overlaid]. All the samples contained 20 mM appropriate buffer and 250 – 300 μM peptide. **A)** GRANDL26AL30C, 1/12 eq Cd(II), pH 7.0; **B)** GRANDL26AL30C, 1/12 eq Cd(II), pH 9.1; **C)** GRANDL16PenL26AL30C, 1/12 eq Cd(II), pH 6.5; **D)** GRANDL16PenL26AL30C, 1/12 eq Cd(II), pH 9.3; **E)** GRANDL16PenL26AL30C, 1.85/3 eq Cd(II), pH 9.3; **F)** GRANDL16PenL19IL23PenL26I, 1.85/3 eq Cd(II), pH 9.2; **G)** GRANDL12AL16CL26AL30C, 1.85/3 eq Cd(II), pH 8.7.

Figure 7.

Sections of ^1H - ^1H NOESY spectra of 3.25 mM $(\text{GRANDL12AL16CL26AL30C})_3$ as a function of added equivalents of Cd(II) at pH 6.0. Peak at 7.91 ppm corresponds to H^{N} of E21 and other peaks displayed in gray correspond to interresidue NOEs ($\text{H}^{\text{N}}_i\text{-H}^{\beta}_{i+1}$) (see text for full description). Colored peaks correspond to intrasidue NOEs of the amide protons (H^{N} , vertical axis) and the β methylene protons (H^{β} , horizontal axis) of Cys: a) $\text{H}^{\text{N}}_{16}\text{-H}^{\beta}_{16}$ for $\text{GRANDL12AL16CL26AL30C}$; b) $\text{H}^{\text{N}}_{16}\text{-H}^{\beta}_{16}$ for $[\text{Cd(II)}(\text{H}_2\text{O})]^{16}\text{apo}^{30}(\text{GRANDL12A16L16CL26AL30C})^-$; and c) $\text{H}^{\text{N}}_{30}\text{-H}^{\beta}_{30}$ for $\text{GRANDL12AL16CL26AL30C}$.

Table 1

List of different derivatives of the **TRI** and **GRAND** peptides.

Peptide	Sequence
TRI	Ac-G LKALEEK LKALEEK LKALEEK LKALEEK G-NH ₂
GRAND	Ac-G LKALEEK LKALEEK LKALEEK LKALEEK LKALEEK G-NH ₂
TRI _{L12AL16C}	Ac-G LKALEEK LKA ^A EEK ^C KALEEK LKALEEK G-NH ₂
TRI _{L16Pen}	Ac-G LKALEEK LKALEEK ^X KALEEK LKALEEK G-NH ₂
GRAND _{L12AL16C}	Ac-G LKALEEK LKA ^A EEK ^C KALEEK LKALEEK LKALEEK G-NH ₂
GRAND _{L26AL30C}	Ac-G LKALEEK LKALEEK LKALEEK LKA ^A EEK ^C KALEEK G-NH ₂
GRAND _{L16Pen}	Ac-G LKALEEK LKALEEK ^X KALEEK LKALEEK LKALEEK G-NH ₂
GRAND _{L16PenL26AL30C}	Ac-G LKALEEK LKALEEK ^X KALEEK LKA ^A EEK ^C KALEEK G-NH ₂
GRAND _{L12AL16CL26AL30C}	Ac-G LKALEEK LKA ^A EEK ^C KALEEK LKA ^A EEK ^C KALEEK G-NH ₂
GRAND _{L12AL16CL26AL30CL33I}	Ac-G LKALEEK LKA ^A EEK ^C KALEEK LKA ^A EEK ^C KAI ^I EEK G-NH ₂
GRAND _{L16PenL23PenL26I}	Ac-G LKALEEK LKALEEK ^X KALEEK ^X KAI ^I EEK LKALEEK G-NH ₂
GRAND _{L16PenL19IL23PenL26I}	Ac-G LKALEEK LKALEEK ^X KAI ^I EEK ^X KAI ^I EEK LKALEEK G-NH ₂

^X = Penicillamine. Residues in red indicate modifications.

Table 2

Apparent pK_{a2} values for **TRI** and **GRAND** peptides.

Peptide	Apparent pK_{a2}
TRI _{L12AL16C}	12.2 ± 0.2
TRI _{L16Pen}	15.8 ± 0.2
GRAND _{L12AL16C}	11.3 ± 0.2
GRAND _{L26AL30C}	9.9 ± 0.2
GRAND _{L16Pen}	15.7 ± 0.2
GRAND _{L16PenL26AL30C}	9.6 ± 0.2 (L26AL30C site)
	16.1 ± 0.2 (L16Pen site)
GRAND _{L12AL16CL26AL30C}	11.8 ± 0.2 (L12AL16C site)
	13.9 ± 0.2 (L26AL30C site)
Grand _{L12AL16CL26AL30CL33I}	11.6 ± 0.2 (L12AL16C site)
	13.5 ± 0.2 (L26AL30C site)
GRAND _{L16PenL19IL23PenL26I}	15.2 ± 0.2 (L23Pen site)
	15.9 ± 0.2 (L16Pen site)

Table 3

Parameters fitted to the PAC data^a

Peptide (c _{Cd(II)} /c _{peptide monomer})	pH	ω_0 (rad/ns)	η	$\Delta\omega_0/\omega_0$ ($\times 100$)	$1/\tau_c$ (μs^{-1})	A ($\times 100$)	Population ^c (%)	χ_r^2
GRANDL26AL30C (1/12)	7.0	0.348(1) 0.245(3)	0.12(2) 0.30(3)	1.5(5) 12(2)	3.6(5) 3.6(5)	1.8(2) 5.1(7)	21 61	1.19
GRANDL26AL30C (1/12)	9.1	0.107(9) ^b 0.347(1)	0.57(9) 0.10(2)	15 ^d 1.4(5)	3.6(5) 2.2(4)	1.5(3) 1.7(2)	18 19	1.29
GRANDL16PenL26AL30C (1/12)	6.5	0.243(3) 0.347(2)	0.31(3) 0.05(8)	14(5) 2.3(3)	2.2(4) 4.2(5)	7.4(6) 1.8(3)	81 17	1.15
		0.245(3) 0.105(7) ^b	0.32(3) 0.59(7)	12(2) 15 ^d	4.2(5) 4.2(5)	6.5(8) 2.3(3)	61 22	
GRANDL16PenL26AL30C (1/12)	9.3	0.345(1) 0.247(3)	0.10(3) 0.26(3)	0.5(5) 12(2)	5.9(7) 5.9(7)	1.7(3) 7.2(7)	17 72	1.11
		0.159(8) ^b	0.77(5)	0(4)	5.9(7)	1.1(4)	11	
GRANDL16PenL26AL30C (1.85/3)	9.3	0.457(2) 0.349(2)	0.0(5) 0.0(3)	1.9(6) 0.4(8)	7.5(1) 7.5(1)	2.3(3) 0.9(2)	29 11	1.23
		0.255(4)	0.22(5)	9(2)	7.5(1)	3.4(5)	43	
		0.125(9) ^b	0.4(1)	12(6)	7.5(1)	1.3(3)	16	
GRANDL16PenL19IL23PenL26I (1.85/3) ^e	9.2	0.461(1)	0.02(4)	0.7(3)	17(2)	6.8(3)	100	1.44
GRANDL12AL16CL26AL30C (1.85/3)	8.7	0.342(6) 0.242(8)	0.148(8) 0(1)	1.8(3) 16(4)	3.8(6) 3.8(6)	5.3(3) 3.9(8)	55 40	1.08
		0.142(2) ^b	0.1(2)	0(2)	3.8(6)	0.5(2)	5	

^aThe numbers in parentheses are the standard deviations of the fitted parameters.

^bIncluding this third NQI significantly improves the fit, but at least two different parameter sets give equally good fits – one possible set of parameters is presented here

^cThe relative population of each species determined using the amplitudes in this Table.

^dFixed in the fit.

^c Although the stoichiometry implies that two sites are occupied, the χ^2_r is not reduced significantly upon inclusion of a second NQI in the fit, and it was not possible to reliably derive parameters for two individual NQIs.

Table 4

% Cd(II) species (4-coordinate and 3-coordinate) based on ^{113}Cd NMR chemical shift values and the ^{113}Cd NMR - ^{111}mCd PAC spectroscopic correlation.

Peptide	^{113}Cd NMR δ (ppm)	% Cd species 4-coordinate (CdS_3O)	% Cd species 3-coordinate CdS_3
GRANDL12AL16CL23Pen	575	100	0
	640	50	50
GRANDL16PenL23PenL26I	678	20	80
	666	29	71
GRANDL16PenL19IL23PenL26I	686	13	87
	681	17	83
GRANDL12AL16CL26AL30C	572	100	0
	589	92	8

Chemical shifts of 579 and 702 ppm are used as values corresponding to a 100 % 4-coordinate and 3-coordinate Cd(II) species, respectively.⁴²

Table 5

Metallation states of the two Pen sites of _{GRAND}L16PenL19IL23PenL26I and the corresponding ^{113}Cd NMR chemical shifts under different experimental conditions.

Metallation state (site A)	Metallation state (site B)	^{113}Cd δ (ppm) (site A)	^{113}Cd δ (ppm) (site B)
$[\text{Cd}(\text{pep})_3]^-$	apo	686	----
$[\text{Cd}(\text{pep})_3]^-$	$[\text{Cd}(\text{pep})(\text{Hpep})_2]^+$	686	ND ^a
$[\text{Cd}(\text{pep})_3]^-$	$[\text{Cd}(\text{pep})_3]^-$	686	681
apo	$[\text{Cd}(\text{pep})_3]^-$	----	691
$[\text{Cd}(\text{pep})(\text{Hpep})_2]^+$	$[\text{Cd}(\text{pep})_3]^-$	ND ^a	691

ND=Not Detected.

^a ^{113}Cd resonances for $[\text{Cd}(\text{pep})(\text{Hpep})_2]^+$ or $[\text{Cd}(\text{pep})(\text{Hpep})_2(\text{OH}_2)]^+$ have never been detected for these or single site peptides such as Cd(II) (triL16C)₃³².